The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies

A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)

(2017) B. M. Slomovitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia

(2017) H. S. Nimeiri et al.   JOURNAL OF CLINICAL ONCOLOGY

From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures

(2009) Melih C. Boruban et al.   EUROPEAN JOURNAL OF CANCER PREVENTION

Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation

(2008) S. A. Byron et al.   CANCER RESEARCH

Rationale for folate receptor alpha targeted therapy in “high risk” endometrial carcinomas

(2008) Monica Brown Jones et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

(2008) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel molecular profiles of endometrial cancer—new light through old windows

(2007) A. Doll et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY